Prognostic and predictive values of oncogenic <i>BRAF, NRAS, c‐KIT</i> and <i>MITF</i> in cutaneous and mucous melanoma

Abstract

Clinical and pathological characteristics of the primary melanoma differed between wild-type and BRAF- or NRAS-mutated tumours. Patients with BRAF-mutated tumours were younger at diagnosis of primary melanoma. Patients carrying mutations showed better responses better to specific kinase inhibitors and interestingly also to systemic cytotoxic chemotherapy.